Shopping Cart 0
Cart Subtotal
USD 0

hepatitis c virus envelope protein e2-pipeline review, h2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017

Summary

According to the recently published report 'Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017'; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 11 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Hepatitis C Virus Envelope Protein E2-E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.

The report 'Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017' outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C and Genital Warts (Condylomata Acuminata).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2

-The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects

-The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hepatitis C Virus Envelope Protein E2-Overview 6

Hepatitis C Virus Envelope Protein E2-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Hepatitis C Virus Envelope Protein E2-Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Hepatitis C Virus Envelope Protein E2-Companies Involved in Therapeutics Development 19

Aviragen Therapeutics Inc 19

Integrated BioTherapeutics Inc 19

Hepatitis C Virus Envelope Protein E2-Drug Profiles 20

BTA-074-Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

CIGB-230-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

E-137-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

E-20-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

hepatitis C (strain H77) vaccine-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

hepatitis C (virus-like particle) vaccine-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

MBL-HCV-1-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibody to Inhibit E2 for Hepatitis C-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Hepatitis C Virus Envelope Protein E2-Dormant Products 32

Hepatitis C Virus Envelope Protein E2-Discontinued Products 33

Hepatitis C Virus Envelope Protein E2-Product Development Milestones 34

Featured News & Press Releases 34

Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma 34

Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released 34

Jun 10, 2013: IBT and Stanford Awarded STTR 35

Aug 30, 2012: Researchers Develop Monoclonal Antibody That Prevents Hepatitis C In Animal Model 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Aviragen Therapeutics Inc, H2 2017 19

Pipeline by Integrated BioTherapeutics Inc, H2 2017 19

Dormant Projects, H2 2017 32

Discontinued Products, H2 2017 33

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Aviragen Therapeutics Inc

Integrated BioTherapeutics Inc

Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017

Summary

According to the recently published report 'Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017'; Hepatitis C Virus Envelope Protein E2 pipeline Target constitutes close to 11 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Hepatitis C Virus Envelope Protein E2-E2 is a viral structural protein found in the hepatitis C virus. It is present on the viral membrane and functions as a host receptor binding protein mediating entry into host cells. It is an important target for the design of entry inhibitors and vaccine immunogens.

The report 'Hepatitis C Virus Envelope Protein E2-Pipeline Review, H2 2017' outlays comprehensive information on the Hepatitis C Virus Envelope Protein E2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 1 and 4 molecules, respectively. Report covers products from therapy areas Infectious Disease which include indications Hepatitis C and Genital Warts (Condylomata Acuminata).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

-The report provides a snapshot of the global therapeutic landscape for Hepatitis C Virus Envelope Protein E2

-The report reviews Hepatitis C Virus Envelope Protein E2 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

-The report reviews key players involved in Hepatitis C Virus Envelope Protein E2 targeted therapeutics and enlists all their major and minor projects

-The report assesses Hepatitis C Virus Envelope Protein E2 targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

-The report summarizes all the dormant and discontinued pipeline projects

-The report reviews latest news and deals related to Hepatitis C Virus Envelope Protein E2 targeted therapeutics

Reasons to buy

-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

-Identify and understand the targeted therapy areas and indications for Hepatitis C Virus Envelope Protein E2

-Identify the use of drugs for target identification and drug repurposing

-Identify potential new clients or partners in the target demographic

-Develop strategic initiatives by understanding the focus areas of leading companies

-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

-Devise corrective measures for pipeline projects by understanding Hepatitis C Virus Envelope Protein E2 development landscape

-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Hepatitis C Virus Envelope Protein E2-Overview 6

Hepatitis C Virus Envelope Protein E2-Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Products under Development by Universities/Institutes 12

Hepatitis C Virus Envelope Protein E2-Therapeutics Assessment 14

Assessment by Mechanism of Action 14

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Hepatitis C Virus Envelope Protein E2-Companies Involved in Therapeutics Development 19

Aviragen Therapeutics Inc 19

Integrated BioTherapeutics Inc 19

Hepatitis C Virus Envelope Protein E2-Drug Profiles 20

BTA-074-Drug Profile 20

Product Description 20

Mechanism Of Action 20

R&D Progress 20

CIGB-230-Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

E-137-Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

E-20-Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

hepatitis C (strain H77) vaccine-Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

hepatitis C (virus-like particle) vaccine-Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

MBL-HCV-1-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV-Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

Monoclonal Antibodies to Target Viral E1 and E2 Proteins for Hepatitis C-Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Monoclonal Antibody to Inhibit E1 and E2 Glycoprotein for Hepatitis C-Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Monoclonal Antibody to Inhibit E2 for Hepatitis C-Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

Hepatitis C Virus Envelope Protein E2-Dormant Products 32

Hepatitis C Virus Envelope Protein E2-Discontinued Products 33

Hepatitis C Virus Envelope Protein E2-Product Development Milestones 34

Featured News & Press Releases 34

Feb 08, 2016: Biota Commences Dosing in Phase 2 Trial of Antiviral Therapy BTA074 for Topical Treatment of Condyloma 34

Oct 31, 2013: Results of Anaconda Pharma's Phase IIa study released 34

Jun 10, 2013: IBT and Stanford Awarded STTR 35

Aug 30, 2012: Researchers Develop Monoclonal Antibody That Prevents Hepatitis C In Animal Model 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Routes of Administration, H2 2017 15

Number of Products by Stage and Routes of Administration, H2 2017 15

Number of Products by Molecule Types, H2 2017 17

Number of Products by Stage and Molecule Types, H2 2017 17


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products under Investigation by Universities/Institutes, H2 2017 12

Products under Investigation by Universities/Institutes, H2 2017 13

Number of Products by Stage and Mechanism of Actions, H2 2017 14

Number of Products by Stage and Route of Administration, H2 2017 16

Number of Products by Stage and Molecule Type, H2 2017 18

Pipeline by Aviragen Therapeutics Inc, H2 2017 19

Pipeline by Integrated BioTherapeutics Inc, H2 2017 19

Dormant Projects, H2 2017 32

Discontinued Products, H2 2017 33

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

Aviragen Therapeutics Inc

Integrated BioTherapeutics Inc

chat_bubbleLet's Chat